Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 17 de 17 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Schuchat A, Houry D, Guy Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6. [Ref.ID 102055]
2.Tiene citas relacionadas Cita con resumen
Cutland CL, Madhi SA, Zell ER, Kuwanda L, Laque M, Groome M, Gorwitz R, Thigpen MC, Patel R, Velaphi SC, Adrian P, Klugman K, Schuchat A, Schrag SJ, and the PoPS Trial Team. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet 2009;374:1909-16. [Ref.ID 87352]
3.Tiene citas relacionadas Cita con resumen
Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman KA, Vázquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-502. [Ref.ID 78392]
4.Tiene citas relacionadas
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, for Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63. [Ref.ID 76657]
5. Cita con resumen
Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM, and the Georgia Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005;365:855-63. [Ref.ID 73007]
6.Tiene citas relacionadas
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein - polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46. [Ref.ID 65954]
7.Tiene citas relacionadas
Shrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig AS, Harrison LH, Reingold A, Stefonek K, Smith G, Gamble M, Schuchat A, for the Active Bacterial Core Surveillance Team. A population-based comparison of strategies to prevent early-onset group B stretptococcal disease in neonates. N Engl J Med 2002;347:233-9. [Ref.ID 62848]
8.Tiene citas relacionadas
Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, for the Active Bacterial Core Surveillance Program on the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24. [Ref.ID 54548]
9.Tiene citas relacionadas
Schuchat A. Neonatal group B streptococcal disease - Screening and prevention. N Engl J Med 2000;343:209-10. [Ref.ID 53349]
10. Cita con resumen
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia D J, Lexau C, Stefonek KR, Patterson J E, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-97. Am J Public Health 2000;90:223-9. [Ref.ID 49246]
11.
Schuchat A. Microbes without borders: infectious disease, public health, and the journal. Am J Public Health 2000;90:181-3. [Ref.ID 49245]
12. Cita con resumen
Schrag SJ, Zywicki S, Farley MM, Reingold A L, Harrison LH, Lefkowitz L B, Hadler JL, Danila R, Cieslak PR, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20. [Ref.ID 48715]
13.
Schuchat A. Group B streptococcus. Lancet 1999;353:51-6. [Ref.ID 42242]
14.
Schuchat A, Robinson K, Wnger JD, Harrison LH, Farley M, Reingold A L, Lefkowitz L, Perkins B A, for the Active Surveillance Team. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-6. [Ref.ID 34504]
15.
Zangwill KM, Schuchat A, Riedo F X, Pinner R W, Koo DT, Reeves M W, Wenger JD. School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. JAMA 1997;277:389-95. [Ref.ID 31028]
16.
Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. Epidemiol Rev 1995;16:374-402. [Ref.ID 23751]
17.Tiene citas relacionadas
Jackson LA, Schuchat A, Reeves M W, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995;273:383-9. [Ref.ID 23195]
Seleccionar todas
 
 1 a 17 de 17